Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug310 | Anti-SARS-CoV2 Serology Wiki | 0.30 |
drug2863 | Performance of the test antigenic and test RT-PCR Wiki | 0.17 |
drug4461 | draw blood Wiki | 0.17 |
Name (Synonyms) | Correlation | |
---|---|---|
drug3485 | SOC Wiki | 0.17 |
drug1643 | Glycine Wiki | 0.17 |
drug1520 | Favipiravir and Hydroxychloroquine Wiki | 0.17 |
drug1166 | Data collection up to 1 year Wiki | 0.17 |
drug2152 | Local standard of care Wiki | 0.17 |
drug3581 | Serologic SARS-CoV-2 screening Wiki | 0.17 |
drug3250 | RUC-4 Compound Wiki | 0.17 |
drug2004 | Intravenous Infusions of Stem Cells Wiki | 0.17 |
drug1568 | Follow-up visit Wiki | 0.17 |
drug311 | Anti-SARS-CoV2 serological controls and serum neutralization Wiki | 0.17 |
drug955 | Cognitive Behavioural Therapy for Insomnia Wiki | 0.17 |
drug1883 | IgG Wiki | 0.17 |
drug1063 | Convalesscent Plasma Wiki | 0.17 |
drug694 | CERC-002 Wiki | 0.17 |
drug2798 | PTC299 Wiki | 0.17 |
drug2010 | Invasive mechanical ventilation Wiki | 0.17 |
drug2621 | Normal saline 0.9% Wiki | 0.17 |
drug558 | Biocollection Wiki | 0.17 |
drug3295 | Recombinant new coronavirus vaccine (CHO cells) high-dose group Wiki | 0.12 |
drug1549 | Flow cytometric analysis Wiki | 0.12 |
drug1290 | Duvelisib Wiki | 0.12 |
drug3296 | Recombinant new coronavirus vaccine (CHO cells) placebo group Wiki | 0.12 |
drug2868 | Peripheral blood draw Wiki | 0.12 |
drug879 | ChAdOx1 nCoV-19 Wiki | 0.12 |
drug3294 | Recombinant new coronavirus vaccine (CHO cell) low-dose group Wiki | 0.12 |
drug3577 | Seraph 100 Wiki | 0.12 |
drug1993 | Interview Wiki | 0.10 |
drug4687 | questionnaire Wiki | 0.07 |
drug963 | Colchicine Wiki | 0.05 |
drug1047 | Convalescent Plasma Wiki | 0.03 |
drug2916 | Placebo Wiki | 0.02 |
drug1775 | Hydroxychloroquine Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D012170 | Retinal Vein Occlusion NIH | 0.17 |
D005157 | Facial Pain NIH | 0.17 |
D007246 | Infertility NIH | 0.13 |
Name (Synonyms) | Correlation | |
---|---|---|
D002386 | Cataract NIH | 0.12 |
D008268 | Macular Degeneration NIH | 0.12 |
D002055 | Burnout, Professional NIH | 0.12 |
D012893 | Sleep Wake Disorders NIH | 0.10 |
D000072657 | ST Elevation Myocardial Infarction NIH | 0.10 |
D008269 | Macular Edema NIH | 0.10 |
D018352 | Coronavirus Infections NIH | 0.09 |
D014652 | Vascular Diseases NIH | 0.09 |
D000077062 | Burnout, Psychological NIH | 0.08 |
D007153 | Immunologic Deficiency Syndromes NIH | 0.08 |
D020447 | Parasomnias NIH | 0.07 |
D003327 | Coronary Disease NIH | 0.07 |
D003095 | Collagen Diseases NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D003550 | Cystic Fibrosis NIH | 0.06 |
D019052 | Depression, Postpartum NIH | 0.06 |
D012216 | Rheumatic Diseases NIH | 0.06 |
D007238 | Infarction NIH | 0.05 |
D006331 | Heart Diseases NIH | 0.05 |
D005355 | Fibrosis NIH | 0.04 |
D003863 | Depression, NIH | 0.04 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.04 |
D009203 | Myocardial Ischemia NIH | 0.04 |
D011014 | Pneumonia NIH | 0.04 |
D007239 | Infection NIH | 0.03 |
D003866 | Depressive Disorder NIH | 0.03 |
D055370 | Lung Injury NIH | 0.03 |
D040921 | Stress Disorders, Traumatic NIH | 0.03 |
D004630 | Emergencies NIH | 0.03 |
D014947 | Wounds and Injuries NIH | 0.03 |
D055371 | Acute Lung Injury NIH | 0.03 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.03 |
D003141 | Communicable Diseases NIH | 0.03 |
D011024 | Pneumonia, Viral NIH | 0.02 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.01 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012636 | Retinal vein occlusion HPO | 0.17 |
HP:0000789 | Infertility HPO | 0.13 |
HP:0000518 | Cataract HPO | 0.12 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0011505 | Cystoid macular edema HPO | 0.10 |
HP:0002721 | Immunodeficiency HPO | 0.08 |
HP:0001658 | Myocardial infarction HPO | 0.04 |
HP:0002090 | Pneumonia HPO | 0.04 |
HP:0000716 | Depressivity HPO | 0.03 |
Navigate: Correlations HPO
There are 33 clinical trials
Descriptive prospective study to investigate the prevalence of COVID 19 during ambulant screening
Description: Prevalence of fever, cough, anorexia, fatigue, diarrhea, vomiting, dyspnee, sore throat and sputum
Measure: Prevalence of symptoms Time: at the ambulant screeningDescription: Prevalence of positive COVID 19 tests in patients planned for surgery, treatment or investigation in the hospital
Measure: Prevalence of positive Sars CoV-2 PCR Time: at the ambulant screeningDescription: Prevalence of positive radiological findings in CT scans of the lungs of planned for surgery, treatment or investigation in the hospital
Measure: Prevalence of positive radiological findings Time: at the ambulant screeningDescription: Prediction of symptoms of COVID 19, based on evaluated baseline questionnaire
Measure: Prediction of symptoms Time: 2 weeks after surgery or treatmentDescription: Prediction of symptoms of COVID 19, based on radiological findings of CT scans
Measure: Prediction of symptoms Time: 2 weeks after surgery or treatmentDescription: Prediction of symptoms of COVID 19, based on COVID 19 PCR results
Measure: Prediction of symptoms Time: 2 weeks after surgery or treatmentA pneumonia of unknown cause detected in Wuhan, China was first reported to the WHO Country Office in China on 31 December 2019. The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020. The spread and severity of the disease is variable from one country to another. Our team as well as many reports suggested that in some countries a " Flu like illness but much worse" was described in October, November and early in December before the WHO announcement. Was it COVID-19?
Description: fever, dry cough, dyspnea, malaise, headache
Measure: Measure frequency of people suffered from unusual flu-like symptoms before December 2019 Time: one monthDescription: serum IgG
Measure: Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible Time: 3 monthThe outbreak linked to SARS-CoV-2 infection was declared a Public Health Emergency of International Concern on 30 January 2020. In all of the emergency Departments, a major reorganization was necessary, notably with the creation of a specific channel for COVID-19 suspect patients. Thus, all caregivers involved must adapt day by day to new places of exercise, new protocols,...The major influx of patients, the precautions to be taken, the specifics of the pathology and its management have profoundly changed daily practice. This exogenous hospital tension impacts all caregivers and more particularly their resilience capacities. Resilience is defined as an ability to recover from or adjust easily to misfortune or change. The Resi-CoV study aims to assess the level of resilience of caregivers of different specialties and trades in the context of covid-19.
Description: CD-RISC-25 : Connor-Davidson Resilience Scale - 25. This scale contain 25 questions each range from 1 to 5. The total is 100 points which means a very high level of resilience.
Measure: compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic. Time: 14 days"For 12 years, the odontology service of the Pitié-Salpêtrière hospital group (GHPS) has been responsible for day and night dental emergency care. Several surveys have been conducted in order to analyze the sociological characteristics of the patients and the typology of the acts performed. These studies indicate that pain is the main reason for consultations, cited by 60 to 80% of patients. So far, very few studies have been done in the context of emergencies. Very recently, a study was undertaken on the satisfaction of patients consulting the odontological emergencies of the GHPS, during a thesis work. This study, carried out in collaboration with the URC Pitié Salpêtrière, under analysis, relates to the satisfaction of patients consulting the odontological emergencies of the GHPS during the day and week, Monday to Friday, excluding night and week emergencies -end (WE). An additional study (URGDENT-NW) aiming at completing this study by focusing on patients consulting the emergency room at night and during the weekend is also in progress. The COVID19 Crisis changed the organization and the venue of patients at the emergency dental service. Therefore this project, based on the same protocol as URGENT and URGDENT-WE, aims at evaluating the Odontology Emergency Reception Service (SAUO) during the COVID 19 epidemy. It will be carried out in the form of a survey whose objective is to assess: on the one hand, the effectiveness of the care provided in this emergency functional unit, and on the other hand the satisfaction of the patients after their passage to the emergency room ."
Description: "Self report measure of pain on the numeric scale 24h after the visit "
Measure: Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable Time: Day 1Description: the pain is measured with the numeric scale
Measure: Pain scores evolution 3 days and 7 days after first visit measured by a numeric scale where 0 is no pain and 10 the worst pain imaginable Time: Day 3 and Day 7Description: Perception of welcoming, waiting time will be measured with a 0-10 numeric scale
Measure: welcoming quality from hospital staff Time: Day 1Description: The patient anxiety will be measured by numeric scale at Day 0, Day 1, Day 3, Day 7
Measure: anxiety score Time: Day 0, Day 1, Day 3, Day 7Description: The perception is measured just after care with a 0-10 numeric scale
Measure: perception of the technical quality of the emergency treatment Time: Day 1This original study will assess the impact of the coronavirus health crisis on the management of patients undergoing medical treatment for cancer, in particularly on the modification of the hospital organization. It will also provide a record of the progress of patients who will have been treated during the epidemic period and infected by the virus. We will also assess the psychological impact of the pandemic in patients but also in caregivers
Description: Proportion of patients with modification of the treatments administered
Measure: To assess the impact of the COVID-19 pandemic on the modifications of treatments administered in hospital (day units) to patients with cancer or malignant hemopathy Time: up to 6 monthsDescription: Proportion of patients with change in the rate of treatment administration
Measure: To assess the impact of the COVID-19 pandemic on the change in the rate of treatment administration in hospital (day units) to patients with cancer or malignant hemopathy Time: up to 6 monthsDescription: Proportion of patients with change in the number of cures administered
Measure: To assess the impact of the COVID-19 pandemic on the number of cures administeredin hospital (day units) to patients with cancer or malignant hemopathy Time: up to 6 monthsDescription: Proportion of patients with change of modality of administration (home administration to replace day hospital administration, teleconsultation uses)
Measure: To assess the impact of the COVID-19 pandemic on change of modality of administration in hospital (day units) to patients with cancer or malignant hemopathy Time: up to 6 monthsDescription: Score of questionnaires of Perceived Stress Scale [0-40 points]
Measure: Evaluate the perceived stress on cancer patients treated in unit day of hospital Time: up to 6 monthsDescription: Score of questionnaires of Impact of Event Scale-Revised [0-88 points]
Measure: Evaluate the post-traumatic stress on cancer patients treated in unit day of hospital Time: up to 6 monthsDescription: Score of questionnaires of sleep disorders (ISI scale, 0-28 points)
Measure: Evaluate the sleep disorders on cancer patients treated in unit day of hospital Time: up to 6 monthsDescription: Score of questionnaires of quality of life (FACT-G scale)
Measure: Evaluate the quality of life on cancer patients treated in unit day of hospital Time: up to 6 monthsDescription: Score of questionnaires of cognitive complaints (Fact-Cog scales; 0-148 points)
Measure: Evaluate the cognitive complaints on cancer patients treated in unit day of hospital Time: up to 6 monthsDescription: Score of questionnaires of Perceived Stress Scale [0-40 points]
Measure: Evaluate the perceived stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness) Time: up to 3 monthsDescription: Score of questionnaires of Impact of Event Scale-Revised [0-88 points]
Measure: Evaluate the post-traumatic stress on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness) Time: up to 3 monthsDescription: Score of questionnaires of burnout ((Maslach Burn Out Inventory scale, 0-132 points)
Measure: Evaluate the burnout on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness) Time: up to 3 monthsDescription: Score of questionnaires of feeling of personal effectiveness (0-30 points)
Measure: Evaluate the feeling of personal effectiveness on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness) Time: up to 3 monthsThe investigators plan to perform an observational study to evaluate the prevalence of burnout, depression and medical errors in a designated exclusive Covid-19 patients hospital in Malaysia, during the Covid-19 pandemic. In addition, the relationship between burnout and depression with medical errors will be assessed. The population studied will be the nurses working in the Intensive Care Unit, who are at higher risk due to the nature of their work at the frontlines of the pandemic.
Description: Prevalence of burnout risk
Measure: Prevalence of burnout among ICU nurses during Covid-19 Time: 2 monthsDescription: Prevalence of depression risk
Measure: Prevalence of depression among ICU nurses during Covid-19 Time: 2 monthsDescription: Prevalence of self perceived medical errors
Measure: Prevalence of self-perceived medical errors among ICU nurses during Covid-19 Time: 2 monthsDescription: To find out if there exists a relationship between burnout, depression and medical errors
Measure: Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19 Time: 2 monthsThe term "sleep hygiene" refers to a series of healthy sleep habits that can improve the ability to fall asleep. These habits are the most effective long-term treatment for people with chronic insomnia. The "Sleep Hygiene Index" is a 13-item questionnaire that evaluates these habits. We are in the process of validation of this questionnaire in the arabic language. We will evaluate these habits in the Lebanese population during the COVID-19 confinement period.
A weekly questionnaire is sent to patients and parents of patients who are vulnerable for infections. Possible symptoms of COVID19 are asked for and use of healthcare services and testing for COVID19. Weekly reports are being send to the national institutions to update advice given to this group.
Description: To describe frequency of cough, fever, diarrhoea, shortness of breath, sore throat, blocked nose, red eyes, headache, joint pain, muscle pain, fatigue, chills, nausea, vomiting, diarrhoea over a year
Measure: To describe COVID19 infection in children/adults who are vulnerable for infection in an outpatients setting Time: 1 yearDescription: Patient/parent reported positive tests for COVID19
Measure: Number of children/adults tested positive for COVID19 Time: 1 yearDescription: Patient/parent reported admissions in hospital because of COVID19
Measure: Number of children/adults admitted in hospital because of COVID19 Time: 1 yearDescription: Patient/parent reported effect of COVID19 on daily activities
Measure: To assess the impact of COVID19 infection on the daily activities of immunosuppressed adults and children Time: 1 yearIt has been suggested that ibuprofen might be associated with more severe cases of coronavirus infections, based on the observation that severe COVID cases had been exposed to ibuprofen, resulting in a warning by the French authorities. This was attributed to: 1. a suggestion that ibuprofen might upregulate ACE-2 thereby increasing the entrance of COVID-19 into the cells, 2. an analogy with bacterial soft-tissue infections where more severe infections on NSAIDs are attributed to an immune-depressive action of NSAIDs, or to belated treatment because of initial symptom suppression, 3. fever is a natural response to viral infection, and reduces virus activity: antipyretic activity might reduce natural defenses against viruses. However fever reduction in critically ill patients had no effect on survival. However, these assertions are unclear: upregulation of ACEII would increase the risk of infection, not necessarily its severity, and would only apply to the use of NSAIDs before the infection, i.e. chronic exposure. It would be irrelevant to the infection once the patients are infected, i.e., to symptomatic treatment of COVID-19 infection. Anti-inflammatory effect masking the early symptoms of bacterial infections resulting in later antibiotic or other treatment is not applicable: there is no treatment of the virus that might be affected by masking symptoms. Antipyretic effect increasing the risk or the severity of infection would apply equally to all antipyretic agents including paracetamol, which share the same mechanism of action for fever reduction. EMA remains prudent about this assertion In addition, excess reliance on paracetamol while discouraging the use of ibuprofen might increase the risk of hepatic injury from paracetamol overdose. Paracetamol is the prime drug associated with liver injury and transplantation, in voluntary and inadvertent overdose or even at normal doses. This might be increased by COVID-related liver function alterations. It is therefore proposed to conduct a case-control study in a cohort of patients admitted to hospital in France with COVID-19 infection.
Description: Describe medications including ibuprofen used prior to admission associated with worse infection in COVID-19 patients in France. Thanks to a questionnaire created for the study, with 5 questions on existing pathology, drugs administrated symptom onset and when, hospitalisation. Each questions have a multiple choice.
Measure: Describe medications used prior to admission associated with worse infection in COVID-19 patients in France. Time: At inclusion dayDescription: Quantify medications including ibuprofen used prior to admission associated with worse infection in COVID-19 patients in France. Thanks to a questionnaire created for the study, with 5 questions: existing pathology, drugs administrated symptoms onset and when, hospitalisation. Each questions have a multiple choice.
Measure: Quantify medications used prior to admission associated with worse infection in COVID-19 patients in France. Time: At inclusion dayDescription: Describe patient characteristics thanks to the same questionnaire.
Measure: Describe other patient characteristics with worse infection in COVID-19 patients in France. Time: At inclusion dayDescription: Quantify patient characteristics thanks to the same questionnaire.
Measure: Quantify other patient characteristics with worse infection in COVID-19 patients in France. Time: At inclusion dayEmerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.
Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 60, measured in blood sample.
Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 60. Time: From Day 0 to Day 60Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 30, measured in blood sample.
Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 30. Time: From Day 0 to Day 30Description: Change of Anti-SARS-Cov2 serological status between Day 30 and Day 60, measured in blood sample.
Measure: Anti-SARS-Cov2 seroconversion between Day 30 and Day 60. Time: From Day 30 to Day 60Description: Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0.
Measure: Anti-SARS-Cov2 seroprevalence at Day 0. Time: Day 0Description: Correlation between seroconversion (measured in blood sample) at Day 60 and sex
Measure: Correlation between seroconversion and socio-demographic factors - sex Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and age
Measure: Correlation between seroconversion and socio-demographic factors - age Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and job type (nurse, physician, etc.)
Measure: Correlation between seroconversion and professional factors - job type Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and personal protective equipment type
Measure: Correlation between seroconversion and professional factors - personal protective equipment type Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and contact with infected individuals
Measure: Correlation between seroconversion and non-professional factors - contact with infected individuals Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and wearing of professional equipment
Measure: Correlation between seroconversion and non-professional factors - wearing of professional equipment Time: Day 60Description: Correlation between seroconversion (measured in blood sample) at Day 60 and respect of barrier gestures
Measure: Correlation between seroconversion and non-professional factors - respect of barrier gestures Time: Day 60In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.
Description: Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up
Measure: Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic Time: Baseline (Before confinement) and 6 months after resumption of follow-upThe COVID-19 pandemic brought new challenges to our nationwide healthcare system, with rapid escalation of the number of affected individuals over a handful of weeks. From March 13, a first set of measures was taken to minimise the spread of the virus, which largely impacted societal and economical daily life. A view days later, on March 17, the country was put in "lockdown" and all non-urgent medical treatments were cancelled or postponed. As recommended by the major scientific fertility societies, all non-ivf fertility treatments were discontinued abruptly, whereas started ivf stimulations were continued until oocyte aspiration, where after a freeze-all strategy was applied. There is little information available for women aiming for pregnancy or embarking on assisted conception. Given the modelling of the pandemic, including the time to peak and subsequent tail, considerable delays in conception to substantially attenuate risk may be required, which will inevitably impact patients wellbeing and overall success rates. A questionnaire was developed to explore patients perspectives on different aspects of their fertility treatment during the COVID-19 pandemic. The questionnaire contains the following sections: - demographic variables; - questions regarding the fertility history of the respondent; - questions regarding the impact of fertility treatment cancellation / postponing fertility treatment during COVID-19 on their life, psychological wellbeing and relationship; - questions regarding continuing medical treatment on their own, or seeking treatment elsewhere; - questions regarding the satisfaction of measures taken by their fertility center regarding the COVID-19 pandemic; - questions regarding expectations of further treatments, with focus on safety issues related to the COVID-19 pandemic. Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
Doctors are at high risk of corona virus infection (COVID-19) during pandemic. The investigators are aiming to explore the emotions, perceived stressors, knowledge and coping strategies of doctors who are working during COVID-19 pandemic in different specialties and in different hospitals by a self assessment questionnaire that was designed and modified from two previously published articles (mentioned in the references), including 7 sections with 88 questions.
Description: Highlighting the emotional aspects, perceived stressors, level of knowledge and coping strategies of doctors who are working during COVID-19 pandemic in different hospitals by using questionnaires that the investigators gave the name "COVID-19 Doctor Stress Questionnaire" that included 7 sections with 88 questions: Demographic data related questions Doctors feelings related questions Factors that help in stressing doctors Factors help in reducing stresses Questions detecting knowledge Attitude towards stresses Motives to complete work Each is answered by the participant and assessed
Measure: Cross-sectional descriptive study: Egyptian Doctors Stresses, Knowledge and Attitude during COVID-19 Pandemic Time: 2 monthsIn mid-February 2020, within the Oise (France) cluster, a case of COVID-19 disease caused by a SARS-CoV2 infection was described among the personnel of the Creail Air Force Base (BA110). This resulted in the beginning of an epidemic controlled by epidemiological measures. One month later, containment measures were taken at the national level, measures that also applied to BA110 personnel. These personnel, exposed to both the initial phase of the epidemic and national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus, particularly at a time when France is lifting the containment measures. It becomes extremely important to understand the levers of viral spread in order to adjust the health measures to be maintained as best as possible. The main objective of this study is to determine the extent of virus diffusion in this highly circulating population, as evidenced by several identified cases of COVID-19.
Description: The percentage of the study population with positive serological status will be determined. ELISA serology test will be used to detect anti-SARS-CoV2 antibodies (IgG and IgM) at Day 0
Measure: Proportion anti-SARS-CoV2 seropositive Time: Day 0Description: Among anti-SARS-CoV2 seropositive participants, the percentage of asymptomatic participants will be determined. COVID-19 symptoms will be measured using a questionnaire.
Measure: Proportion of asymptomatic anti-SARS-CoV2 seropositive participants Time: Day 0Description: The serological results obtained using the reference ELISA test results (detecting the presence of IgG and IgM antobodies) and using a second ELISA test detecting the presence of antibodies specifically directed against the Receptor Binding Domain and the Spike protein trimer of SARS-CoV2 virus will be compared.
Measure: Agreement between the anti-SARS-CoV2 serological results obtained using two different techniques (detecting the presence of different antibodies) Time: Day 0Description: Among anti-SARS-CoV2 seropositive participants, the percentage of participants with a positive response to serum neutralization will be determined.
Measure: Proportion of serum neutralization positive Time: Day 0Description: The evolution of the antibody level over time will be determined using repeated serodiagnoses at 3 and 9 months.
Measure: Change of antibody level over time Time: 3 months and 9 months after Day 0The lockdown of the French population is a health measure put in place in response to the pandemic linked to a new coronavirus, SARS-CoV-2 (Covid-19). After a health campaign to recommend hygienic "barrier gestures" and social distancing, the decision to confine the population at the national level was decided by the executive from Monday 16 March to Monday 11 May 2020. The national confinement implies the restriction of movement to the strict necessary, outings near the home and the closure of schools and communities. These decisions have led to an unprecedented state of stress for the entire French population, the consequences of which are unknown in the short, medium or long term. The objectives of this study are to evaluate the psychological impact of the confinement on adolescents with or without chronic disease and also the difficulties and fears engendered by deconfinement .
Description: Scale 0-21
Measure: Anxiety score from the Generalized Anxiety Disorder 7 (GAD-7) questionnaire Time: At inclusionDescription: Scale 0-60
Measure: Depression score from the Adolescent Depression Rating Scale (ADRS) questionnaire Time: At inclusionDescription: 8 items that are scored on a four-point scale and 3 sub scales: intrusion (4 items); avoidance (4 items) and arousal (5 items)
Measure: Post traumatic score questionnaire: Children's Revised Impact of Events Scales -CRIES13 Time: At inclusionDescription: a question on the quality and quantity of sleep will be asked to the teenager on a questionnaire
Measure: Presence or absence of difficulty in falling asleep, sleeping Time: At inclusionDescription: a question on the presence or absence of feeding difficulty will be asked to the teenager on a questionnaire
Measure: Presence or absence of feeding difficulty Time: At inclusionDescription: a question on the presence or absence of difficulty performing physical activity will be asked to the teenager on a questionnaire
Measure: Presence or absence of difficulty performing physical activity Time: At inclusionDescription: a question on the presence or absence of toxic consomption will be asked to the teenager on a questionnaire
Measure: Presence or absence of toxic consomption (drug, acohol) during the lockdown Time: At inclusionDescription: A question on the presence or absence of difficulties with social interactions will be asked to the teenager on a questionnaire
Measure: Presence or absence of difficulties with social interactions Time: At inclusionDescription: Presence or absence of difficulties with familial interactions
Measure: Presence or absence of difficulties with familial interactions Time: At inclusionEmpathy, which can be briefly defined as understanding and feeling of one's thoughts upon experiences. It has been gaining importance in health care. A great majority of the literature has been focusing on the aspect of physician and health care provider yet recently establishing or measuring empathy has been performed with the undergraduate students. Since empathy and its related dimensions are important to integrate a better skill to provide in health care, measuring empathy gained attention. However, there might be lacking some tools which assess empathy directly such as the Empathic Tendency Scale and the Empathic Skill Scale in the Turkish language, yet these were discussed as cannot be quite modifiable to some specific sub-groups such as health sciences students. Thus, this study is aimed to study for the reliability, validity, and cross-cultural adaptation of the Turkish version of the Jefferson Scale of Empathy for undergraduate health care students.
Description: The Turkish version of Jefferson Scale of Empathy Health Professional Students (JSE-HPS) will be applied to participants. The minimum and maximum scores for JSE-HPS can be reached to 20 and 140, respectively. The more the higher scores indicate more empathic aspect or vice versa.
Measure: Jefferson Scale of Empathy Health Professional Students Questionnaire Time: BaselineDescription: The Turkish version of Jefferson Scale of Empathy Health Professional Students (JSE-HPS) will be applied to participants. The minimum and maximum scores for JSE-HPS can be reached to 20 and 140, respectively. The more the higher scores indicate more empathic aspect or vice versa.
Measure: Jefferson Scale of Empathy Health Professional Students Questionnaire Time: 1 week after baselineDescription: The Turkish version of Empathic Tendency Scale (ETS) Questionnaire will be applied to participants. The minimum and maximum scores can be taken from the tool are 20 and 100, respectively in which higher scores indicate better empathic attitude or vice versa.
Measure: Empathic Tendency Scale (ETS) Questionnaire Time: BaselineDescription: Basic Form gathers some information related participants' age, gender etc.
Measure: Demographic Data Form Time: BaselineThis is a cross-sectional survey which will be distributed online between surgeons. The survey was proposed by a consensus of consultants of surgery and revised by an improvement consultant. It consists of a semi-structured questionnaire that is provided in English language. The survey will be conducted online through an online survey development cloud-based software (SurveyMonkey®; San Mateo, CA, USA). Participants will be aware of the nature of the survey and informed that they will be listed as co-authors. Collected data will be confidential and anonymous. The first sector of the questionnaire includes trainee demographics and baseline characteristics. Then the questionnaire aims to compare the trainee experience before and after the pandemic with focus on research activities, clinical, and surgical practice.
Description: A questionnaire designed based on the literature review to assess Burnout
Measure: Change in Burnout before COVID-19 and during COVID-19 Time: 1 year before COVID-19 versus during the COVID-19 pandemic (Mrach-June 2020)Description: A questionnaire designed based on the literature review to assess Job satisfaction
Measure: Change in Job satisfaction before COVID-19 and during COVID-19 Time: 1 year before COVID-19 versus during the COVID-19 pandemic (Mrach-June 2020)A questionnaire is developed based on the literature and clinical experience. Initial testing will be performed on 20 patients. The first and second sectors include patient demographics and patient clinical diagnosis/scheduled surgery, respectively. The following sectors examine the process of delivering the cancellation/re-scheduling; care after cancellation and whether the procedure conducted elsewhere or not; and the impact of cancellation on patient health, career, and financial aspects.
Description: A questionnaire based on the literature review to access the quality of the life of the patients
Measure: Quality of Life of the patients Time: During the COVID-19 pandemic 6 months (March-October 2020)Hospital mortality attributed to SARS-CoV-2 in France increased daily by 28% in the week before confinement. The week following this decision, the daily increase was 30%. During the week of the second week of confinement, it started a decline of 19% estimated over the last 5 days, reaching the cumulative number of 2606 deaths on 29/3 (site https://www.eficiens.com/coronavirus- personal statistics / and calculation). The diagnosis of viral carriage by RT-PCR is reserved for symptomatic cases among caregivers, due to the shortage of available tests and the cumbersome implementation. The carrier diagnosis is the benchmark, on which are implemented the therapeutic strategies and established the national statistics. It can present false negatives, linked to a research too early or too late in relation to the infection, or to a technical defect of the nasal swab sample. Caregivers on the front line in patient care, in hospitals or in the city, have only partial access to this diagnostic test, depending on the existence of symptoms. The implementation of a systematic serological screening, planned by the government and which cannot be based only on the search for the virus, will make it possible to inform the caregivers presenting symptoms or not, of their serological status, and therefore of their degree immunity or, on the contrary, susceptibility to infectious contacts. It should therefore be very voluntarily requested. On the occasion of this screening, the constitution of the COVID-3S cohort will make it possible to verify the degree of contamination in an asymptomatic population, information which is sorely lacking for the estimation of the immune coverage of the population. The implementation of the Covid-3S study will be based on the work of the National Reference Center of Pr B Lina, from the COVID-SER cohort, for the selection of the most efficient test (s). It seems useful to initiate the constitution of this cohort as soon as possible in relation to the evolution of the epidemic. Pending receipt of official recommendations, the lack of knowledge of the performance of serological tests means that it should be applied first to health professionals, better able to appreciate its limits, for the initial period before determining a validated serological screening strategy. Once the strategy has been specified, the gradual expansion of screening to the patient population will provide a more representative basis for the construction of epidemiological models for evaluating strategies.
Description: Estimated number of deaths avoided by the various population protection strategies, estimated by applying these strategies to the realistic virtual population.
Measure: Establishment of a reliable prediction model for the effectiveness of virus control Time: 18 monthsNon-urgent medical care, such as fertility treatments, has been massively postponed during the past weeks due to the COVID19 pandemic. The lockdown and the closure of IVF centers might cause anxiety and depression among infertile couples, who are already exposed to the distressing experience of infertility and for whom the wait for a baby already appears unending. Few data are available regarding the impact of SARS-CoV-2 on pregnant women and foetus, or on fertility. This study aims to assess the views of infertile couple regarding the potential risks of COVID during their fertility treatment and their personal experience of the COVID pandemic and their expectation for further treatment .
Description: Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment, via a survey
Measure: Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation Time: 1 dayDescription: . Risk assessment by the patient, via a survey, regarding SARS-CoV-2 during a fertility treatment or during pregnancy. Perception of the risks linked to SARS-CoV-2 during their fertility treatment or during a pregnancy
Measure: Risk assessment Time: 1 dayDescription: Patients'expectations regarding the management of an abrupt closure of the fertility center, via a survey
Measure: Patients'expectations regarding the management of an abrupt closure of the fertility center Time: 1 dayImpacts of the Covid-19 epidemic and associated lockdown measures on the management, health and behaviors of cystic fibrosis patients during the 2020 epidemic
Description: Number of consultations cancelled or postponed by the health professional or patient of consultations (medical and paramedical),
Measure: Cancellation or postponement of consultations by the health professional or patient, Time: Up to 6 monthsDescription: Number of consultations cancelled by the teleconsultation/replacement patient,
Measure: Patient cancellation of teleconsultations/telecare replacement, Time: Up to 6 monthsDescription: Number of consultations cancelled or postponed by the health care institution or by the patient of hospitalizations (acute or scheduled)
Measure: Cancellation or postponement by the health care institution or by the patient of hospitalizations (scheduled or unscheduled), Time: Up to 6 monthsDescription: Number of patients affected by the change in the modality of administration of antibiotic cures (intravenous instead of intravenous administration).
Measure: Change in the modalities of administration of antibiotics cures (oral instead of intravenous administration). Time: Up to 6 monthsDescription: Cancellation or postponement by the patient of consultations (medical or paramedical) Patient cancellation of teleconsultations/telecare proposed by the health professional Cancellation or postponement by the patient of hospitalizations (acute or scheduled)
Measure: The reduction of each of the elements of care provision and health care utilization: Time: Up to 6 monthsDescription: Intravenous instead of intravenous administration
Measure: The change of modality of administration of antibiotic cures Time: Up to 6 monthsDescription: Questionnaire about taking or not taking treatment during confinement
Measure: Compliance Time: Up to 6 monthsDescription: Scale 0-21
Measure: Anxiety and stress (at risk of being affected by COVID-19 or at risk of being treated less well) Time: Up to 6 monthsDescription: A questionnaire on the presence or absence of toxic consumption
Measure: Presence or absence of toxic consumption (drug, alcohol) during the lockdown Time: Up to 6 monthsDescription: Experience and social representations of confinement by cystic fibrosis patients (evaluated by qualitative methods)
Measure: Evaluation of the knowledge, experience and social representations of the risk of Covid-19 Time: Up to 6 monthsDescription: Role of social inequalities in the consequences of containment assessed by qualitative methods
Measure: Assessing the role of social inequalities in the consequences of lockdown Time: Up to 6 monthsDescription: Prevalence of suspected and/or confirmed Covid-19 infections in patients with cystic fibrosis
Measure: Suspected and/or confirmed Covid-19 in patients with cystic fibrosis. Time: Up to 6 monthsSpread of COVID-19 in the world has led to a shift in teaching and learning techniques to online methods in order to prevent transmission of the disease. Misr International University (MIU) has an established online learning system that has been used together with face-to-face classes. The aim of this study is to assess and compare the satisfaction and perceptions of full-time teaching staff and undergraduate students regarding online learning during COVID-19 crisis.
Description: Assess level of satisfaction with online learning using a questionnaire
Measure: Satisfaction with online learning Time: 1 monthDescription: Assess level of knowledge about COVID-19 using a questionnaire
Measure: Knowledge about COVID-19 crisis Time: 1 monthDescription: Assess level of perception of COVID-19 crisis using a questionnaire
Measure: Perception of COVID-19 crisis Time: 1 monthThe aim of this questionnaire survey is to evaluate the improvement in vision-related quality of life before and after cataract surgery using the National Eye Institute Visual Function Questionnaire 25 and the delay of improvement in the COVID-19 pandemic.
Description: Extent of improvement of vision-related qualitiy of life due to cataract surgery measured with the National Eye Institut Visual Function Questionnaire 25.
Measure: Improvement Vision-related quality of life Time: 3 monthsDescription: Delay of improvement of vision-related qualitiy of life in the COVID-19 pandemic measured in days between the originally scheduled operation and the actual operation date
Measure: Delay of Vision-related quality of life Time: 3 monthsDescription: Visual acuity difference between visual acuity at the time of indication for cataract surgery, on the day of surgery and one month postoperatively.
Measure: Visual acuity Time: 1 monthAssessing the knowledge and practice of GIT endoscopists toward the use of PPE.
Description: Online questionnaire
Measure: The knowledge and attitude toward PPE during endoscopy Time: 2 monthsPostpartum depression (PPD) represent around 15% of birth in developed countries. The context of the COVID-19 epidemy represents a possible source of additional emotional distress. The objective of this study is to determine the screening prevalence and risk factors of postpartum depression, among women who deliver in fourth hospital in the North of France in the context of the COVID epidemy.
Description: Variation of prevalence of clinically-significant post-partum depressive symptoms
Measure: Variation of prevalence of clinically-significant post-partum depressive symptoms Time: up to 35 days after deliveryCOVID-19 is an infectious disease caused by the last coronavirus discovered, called SARS-CoV-2. Symptoms encountered in COVID-19 are: cough, breathing difficulties (dyspnea, chest pain, etc.), pyrexia, anosmia (loss of smell) and/or dysgeusia (loss of taste), but also ENT symptoms (rhinitis type, odynophagia), headaches, asthenia, muscle pain, confusion and diarrhea. Infection with SARS-CoV-2 can also be asymptomatic. COVID-19 can be passed from person to person by respiratory droplets expelled when a person speaks, coughs or sneezes. The currently estimated incubation period ranges from 1 to 14 days, and most often this is around 5 days. According to a literature review, there is strong evidence that COVID-19 has an impact on mental health (anxiety being the most common symptom) whether in the general population, healthcare workers or vulnerable populations. The objective of this project is to assess mental health and sleep disorders within two populations: elderly patients and nursing staff.
Description: The IES-R is a 22-item self-report measure that assesses subjective distress caused by traumatic events.Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88) and subscale scores can also be calculated for the Intrusion, Avoidance, and Hyperarousal subscales.
Measure: Impact Event Scale-Revised (IES-R) Time: 15 minutesDescription: Self-administered patient questionnaire used as a screening tool and severity measure for generalised anxiety disorder (GAD).The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. When used as a screening tool, further evaluation is recommended when the score is 10 or greater.
Measure: Generalised Anxiety Disorder-7 (GAD-7) Time: 15 minutesDescription: The PHQ-9 is the depression module, which scores each of the nine DSM-IV criteria as "0" (not at all) to "3" (nearly every day). It has been validated for use in primary care. It is not a screening tool for depression but it is used to monitor the severity of depression and response to treatment.
Measure: Patient Health Questionnaire-9 (PHQ-9) Time: 15 minutesDescription: The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia.The dimensions evaluated are: severity of sleep onset, sleep maintenance, and early morning awakening problems, sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and distress caused by the sleep difficulties. A 5-point Likert scale is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
Measure: Insomnia severity index (ISI) Time: 15 minutesDescription: Age, gender, familial status, home status (living alone/family support/healthcare support/ retirement home).
Measure: Demographic data Time: 1 yearDescription: Hospitalization duration
Measure: Hospitalization duration Time: 1 yearDescription: Hospitalization within the intensive care unit (yes/no) with or without intubation
Measure: ICU stay Time: 1 yearDescription: History of chronic diseases
Measure: Medical history Time: 1 yearDescription: Alcohol consumption : none - stable - increased - diminished
Measure: Alcohol consumption Time: 1 yearDescription: Tobacco consumption : none - stable - increased - diminished
Measure: Tobacco consumption Time: 1 yearThe aeronautical community was also affected and greatly impacted economically and socially by the Covid-19 pandemic. Away from the acute phase, the epidemiological impact and the consequences of this disease within the French aviation flight crew population must be assessed. This study is aimed at providing original epidemiological data among civil and military aircrew, prior to possible prevention strategies or countermeasures to optimize risk management in terms of aviation safety and to promote, if necessary, future targeted studies.
Description: Prevalence of COVID-19 infection will be estimated on the basis of the replies to the questionnaire
Measure: Prevalence of COVID-19 infection among French military professional aircrew Time: At enrollmentDescription: Predictive factors of COVID-19 infection will be assessed using a top-down logistic regression model taking into account socio-demographic and occupational variables.
Measure: Predictive factors of COVID-19 infection Time: At enrollmentDescription: Techniques used for COVID-19 screening will be estimated on the basis of the replies to the questionnaire (among participants who reported being tested for COVID-19)
Measure: Techniques used for COVID-19 screening Time: At enrollmentDescription: Reasons for COVID-19 screening will be estimated on the basis of the replies to the questionnaire (among participants who reported being tested for COVID-19)
Measure: Reasons for COVID-19 screening Time: At enrollmentDescription: Experienced symptoms of COVID-19 will be estimated on the basis of the replies to the questionnaire (among participants who reported being infected)
Measure: Experienced symptoms of COVID-19 Time: At enrollmentDescription: Medical care of COVID-19 will be estimated on the basis of the replies to the questionnaire (among participants who reported being infected)
Measure: Medical care of COVID-19 Time: At enrollmentDescription: Social consequences of the COVID-19 pandemic will be estimated on the basis of the replies to the questionnaire
Measure: Social consequences of the COVID-19 pandemic Time: At enrollmentDescription: Factors associated with pejorative consequences of the COVID-19 pandemic will be assessed using a top-down logistic regression model taking into account socio-demographic and occupational variables.
Measure: Factors associated with pejorative consequences of the COVID-19 pandemic Time: At enrollmentEmerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission is by droplet route, with an R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. During the period of containment, the majority of students from the Lyon-Bron Military Medical Schools were sent as reinforcement in Army Training Hospitals and in the Military Reanimation Unit (Mulhouse). Some students developed symptomatic forms of SARS-Cov-2 infection, documented by positive PCR, during Operation Resilience or on their return from the mission. The Lyon-Bron Military Medical Schools staff, exposed both to the initial phase of the epidemic and to national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus.
Description: The proportion of anti-SARS-CoV2 seropositive participants will be determined. ELISA serology test will be used to detect anti-SARS-CoV2 antibodies (IgG and IgM) at Day 0.
Measure: Proportion of anti-SARS-CoV2 seropositive participants Time: Day 0Description: The proportion of asymptomatic participants (among anti-SARS-CoV2 seropositive participants) will be determined. COVID-19 symptoms will be measured using a questionnaire.
Measure: Proportion of asymptomatic participants (among anti-SARS-CoV2 seropositive participants) Time: Day 0Description: Correlation coefficient between medical risk factors and a positive serology will be assessed using a step-by-step top-down regression analysis.
Measure: Correlation coefficient between medical risk factors and a positive serology Time: Day 0Description: Correlation coefficient between epidemiological risk factors and a positive serology will be assessed using a step-by-step top-down regression analysis.
Measure: Correlation coefficient between epidemiological risk factors and a positive serology Time: Day 0Description: Correlation coefficient between social risk factors and a positive serology will be assessed using a step-by-step top-down regression analysis.
Measure: Correlation coefficient between social risk factors and a positive serology Time: Day 0The COVID-19 pandemic represents a threat to rheumatology patients. National advice for patients to 'shield' is based on risk stratification of therapies and other risk factors. While the epidemiology of COVID-19 in the rheumatological population is largely unknown large case registries are beginning to show potential drug treatment interactions. Strict self-isolation (shielding) has been recommended for those deemed 'high risk' although its impact on the likelihood of COVID-19 infection and health related quality of life (HRQoL) is unclear. The study aims to explore how this unprecedented situation has impacted the Trust patients primarily evaluating prevalence of the infection, effect of stringent social distancing (shielding) and Quality of Life (QOL). This will be done via a voluntary questionnaire, sent via text messaging at 6 and 12 months.
Description: percentage of cases
Measure: Prevalence of COVID 19 Time: 1 yearDescription: number of deaths per 1000 individuals
Measure: Mortality rates from COVID 19 Time: 1 yearDescription: mental and physical component scores through patient reported outcomes. Normative score set at 50 with minimum score being 0 and maximum score being 100. Scores >50 indicate better mental or physical health than the mean. Scores <50 indicate worse mental or physical health than the mean
Measure: Health related quality of life - Short Form 12 Time: 1 yearThe epidemic of coronavirus induces a major influx of patients implying a rapid modification of the organizations, a work overload and a significant stress for the care teams and supports of the hospitals of the Assistance Publique - Hôpitaux de Paris (AP-HP) . To this is added the impact on each professional of the large number of very severe patients to be treated, of death and the anxiety of contamination, reinforced by the actual cases of staff themselves sick. Emergency phone numbers for professionals in the event of psychological suffering were quickly put in place at the AP-HP and Hospitals level. The objective of this study is to assess the psychopathological and psycho-traumatic consequences of this exceptional situation on the staff, during the epidemic and at a distance from it, in order to be able to target the solutions to be implemented. Hypothesis is that some personnel may develop one or more of the following disorders: adjustment disorder or other anxiety disorder, acute stress disorder, post-traumatic stress disorder (PTSD), and depressive episodes as defined in the DSM-5. This study also aimes to assess effect of support measures put in place, by comparing the evolution of those who benefited from those who did not use them, as well as the risk factors specific. The results will make it possible to have an estimate of the percentage of people who may require specific support, and to identify the staff most at risk, and thus predict the importance of the circuits and structures for support of staff which will be necessary in the short and long term. The main anticipated risk factors are: being a nurse, having a low number of years of professional experience, and being on the front line of care for affected patients.
Description: Rate of respondents with a PTSD defined as score higher or equal to 32 for PCL-5 (Post-Traumatic Stress Disorder Checklist Scale, version DSM-5) at, at least, one of the three measures (inclusion, M3 or M6)
Measure: Prevalence of PTSD among APHP staff during the COVID-19 epidemic and at a distance (inclusion, 3 months or 6 months). Time: 6 monthsDescription: Rate of respondents with an Anxiety Disorder defined as score higher or equal to 8 for the HAD-A subscale (Hospital Anxiety and Depression - Anxiety subscale) independently at each measure (inclusion, M3 and M6)
Measure: Prevalence of Anxiety Disorder among APHP staff during the COVID-19 epidemic and at a distance (inclusion, 3 months and 6 months). Time: baseline, 3 months and 6 monthsDescription: Rate of respondents with a Depressive Disorder defined as score higher or equal to 8 for the HAD-D subscale (Hospital Anxiety and Depression - Depression subscale) independently at each measure (inclusion, M3 and M6)
Measure: Prevalence of Depressive Disorder among APHP staff during the COVID-19 epidemic and at a distance (inclusion, M3 and M6). Time: baseline, 3 months and 6 monthsAn observational cross sectional questionnaire study looking into facial hair of hospital doctors during the COVID-19 pandemic, and how personal protective equipment guidance has affected this.
Description: Our primary outcome measure was change in facial hair between January 2020 (before guidance was circulated in the UK about facial hair), and during April 2020 (after guidance was circulated relating to PPE appropriate facial hair)
Measure: Change in facial hair between January 2020 and during April 2020. Time: January 2020 and during April 2020.Description: Does facial hair change adhere to the PPE guidance from PHE
Measure: Does facial hair change adhere to the PPE guidance from PHE Time: January 2020 and during April 2020.The new type of Coronavirus (SARS-CoV-2) epidemic puts great pressure on health systems around the world. A large number of people are hospitalized in intensive care units due to acute respiratory distress syndrome due to SARS-CoV-2. Common symptoms seen with SARS-CoV-2 include fever, cough, and dyspnea, as well as pneumonia, severe acute respiratory distress syndrome, renal failure, and even death. Many patients develop mild to moderate disease without pneumonia. The respiratory condition of some patients continues to worsen gradually and develop acute respiratory distress syndrome, which usually requires mechanical ventilation support. Exercise capacity and health status of individuals who survived severe acute respiratory distress syndrome are lower than the general population. Persistent physical, cognitive, and psychosocial disorders can be seen in people who have survived acute respiratory distress syndrome. Given the clinical and radiological heterogeneity of COVID-19, it is important to have a simple tool for the disease to monitor the course of symptoms and the impact of symptoms on patients' functional status. Klok FA et al. developed the Post-COVID-19 Functional Status Scale (PCFS). PCFS can be evaluated for functional sequelae after discharge from the hospital, at 4 and 8 weeks after discharge, to directly monitor recovery, and at 6 months. The aim of this study is to investigate the validity and reliability of PCFS in Turkish population. Research permission to investigate the validity and reliability of PCFS in the Turkish population was obtained from the developer of the PCFS.
Description: It has been proposed as a tool to measure the full spectrum of functional outcomes following COVID-19. Post-COVID-19 Functional Status scale was reported to be used to monitor functional status. Scoring varies between 0-4. The expression 0 in PCFS indicates that there is no functional limitation. Grade 4 describes patients with severe functional limitations that require assistance with activities of daily living.
Measure: Post-COVID-19 Functional Status Scale (Turkish version) Time: Through study completion, an average of 1 yearDescription: Dyspnea will be assessed by the Modified Medical Research Council (MMRC) dyspnea scale. Individuals are asked to choose the expression that best describes their dyspnea level. Scoring in MMRC varies between 0-4 points. "0 points" means that there is no dyspnea; "4 points" indicates that there is a perception of dyspnea during basic daily life activities such as dressing.
Measure: Dyspnea assessment Time: Through study completion, an average of 1 yearDescription: The Barthel index was developed by Mahoney and Barthel in 1965. It is an index that is simple, understandable and includes all parameters of daily life activities. Its Turkish validity and reliability were made by Küçükdeveci et al. It consists of 10 sub-headings: eating, bathing, self-care, dressing, bladder control, bowel control, toilet use, chair / bed transfer, mobility, and use of stairs. Its scoring ranges from 0 to 100.
Measure: Evaluation of daily living activities Time: Through study completion, an average of 1 yearDescription: The London Chest Activities of Daily Living Scale, developed by Garrod et al., will be used to evaluate the structural validity of the Post-COVID-19 Functional Status Scale. This questionnaire consists of 15 items and four components: personal care (4 items), housework (6 items), physical (2 items) and leisure (3 items). Each item is scored between 0 and 5. High scores show that the limitation in daily living activities is greater. The total score can reach 75 at most. The validity and reliability study of the questionnaire for the Turkish population has been conducted.
Measure: Assessment of the structural validity of the Post-COVID-19 Functional Status Scale Time: Through study completion, an average of 1 yearSeveral publications document the occurrence of symptoms that persist or occur late. The identification of the observed clinical manifestations and their clinical and paraclinical description are essential to better understand the natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible late manifestations, and to identify potential management options for patients. Since this type of event is infrequent, a large-scale national multicenter cohort study focusing on symptomatic patients is needed.
Description: Describe the frequence of asthenia between its onset and its disappearance. Assessment at baseline, then 4, 6 and 12 months.
Measure: Clinical description of asthenia Time: At the end od the study, an average of 22 monthsDescription: Frequence of dyspnea between its onset and its disappearance. Assessment at baseline, then 4, 6 and 12 months. Assessment at baseline, then 4, 6 and 12 months.
Measure: Clinical description of dyspnea Time: At the end od the study, an average of 22 monthsDescription: Frequence of thoracic disorders between its onset and its disappearance. Assessment at baseline, then 4, 6 and 12 months. Assessment at baseline, then 4, 6 and 12 months.
Measure: Clinical description of thoracic disorders Time: At the end od the study, an average of 22 monthsDescription: Frequence of neurological disorders between its onset and its disappearance. Assessment at baseline, then 4, 6 and 12 months. Assessment at baseline, then 4, 6 and 12 months.
Measure: Clinical description of neurological disorders Time: At the end od the study, an average of 22 monthsDescription: Frequence of anosmia disorders between its onset and its disappearance. Assessment at baseline, then 4, 6 and 12 months. Assessment at baseline, then 4, 6 and 12 months.
Measure: Clinical description of anosmia Time: At the end od the study, an average of 22 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports